Latin America Roundup: Brazil, Mexico lay out regulatory priorities
“…Mexico’s Federal Commission for the Protection Against Health Risks (COFEPRIS) also recently made public its priorities and work agenda for 2024, some of which parallel those laid out by ANVISA.
In a document released on 30 January, COFEPRIS described efforts to promote regulatory certainty, improve confidence in its processes, and expand digitalization as a strategy to speed approvals.
COFEPRIS said 2024 would see the launch of its biosimilars unit and pharmaceutical development committee, both of which share the goal of expanding Mexican manufacturing. The agency also promised to refine rules for conducting clinical research “with the aim of achieving competitive service times.”…”